Margin grew by 1,290bps YoY: Pfizer's EBIDTA margin for the quarter grew 1,290bps YoY to 29.3% from 16.4% due to overall decline in costs. Its material cost declined by 30bps YoY to 41.9% from 42.2% due to a profitable product mix. Personnel expenses declined by 60bps to 13.9% from 14.5%. Other expenses declined by 1,210bps to 14.9% from 27.0% as Q2FY17 had one-off expenses. The...